Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.87 CNY | -4.21% | -8.84% | -25.96% |
May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.96% | 473M | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug